2017 Named Executive Officer Compensation
EX-10.1 2 d332452dex101.htm EX-10.1 EX-10.1
Exhibit 10.1
2017 Named Executive Officer Compensation
| Name | Base Salary (Annual Rate) (1) | Target Performance Bonus (% of Base Salary) (2) | Options Granted (3) | RSUs Awarded (4) | ||||||||||
| Lisa D. Earnhardt | $ | 540,000 | 75% | 252,000 | 54,000 | |||||||||
| President and Chief Executive Officer | ||||||||||||||
| Jeryl L. Hilleman | $ | 367,900 | 45% | 70,000 | 15,000 | |||||||||
| Chief Financial Officer | ||||||||||||||
| Richard E. Kaufman | $ | 342,900 | 35% | 42,000 | 9,000 | |||||||||
| Senior Vice President and Chief Operating Officer | ||||||||||||||
| James W. Stambaugh | $ | 290,000 | 35% | 52,500 | 11,300 | |||||||||
| Vice President, Clinical Affairs | ||||||||||||||
| (1) | Effective January 1, 2017. |
| (2) | The actual bonus to be awarded will be at the Compensation Committee’s discretion based on the Company’s performance against financial and clinical milestone objectives as determined by the Compensation Committee. |
| (3) | Granted by the Compensation Committee on January 18, 2017. The exercise price per share of such option grant is $13.05, the closing price of the Company’s common stock on the NASDAQ Global Market on the date of grant. The shares subject to each option will vest commencing January 1, 2017 in equal monthly installments over four years following a six month cliff vesting period, except for Mr. Stambaugh’s whose vesting will commence on March 1, 2017. |
| (4) | Granted by the Compensation Committee on January 18, 2017. Restricted stock units will vest commencing January 1, 2017 in equal annual installments over three years, except for Mr. Stambaugh’s whose vesting will commence on March 1, 2017. |
